AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
AccuStem Sciences (OTCQB: ACUT) announced an expansion of blood-based testing capabilities through its partnership with EmeritusDX. The collaboration includes the installation of the Promega Maxwell RSC system at EmeritusDX for high-throughput microRNA extraction from blood samples.
This expansion will support AccuStem's MSC test, the first diagnostic using microRNAs to stratify lung nodules for malignancy risk. Additionally, EmeritusDX has increased its sales force by 35% and launched the Syntara™ platform for personalized treatment strategies in hematologic diseases.
AccuStem Sciences (OTCQB: ACUT) ha annunciato un ampliamento delle capacità di test basati sul sangue tramite la sua partnership con EmeritusDX. La collaborazione prevede l'installazione del sistema Promega Maxwell RSC presso EmeritusDX per l'estrazione ad alto rendimento di microRNA da campioni di sangue.
Questa espansione supporterà il test MSC di AccuStem, il primo diagnostico che utilizza i microRNA per stratificare i noduli polmonari in base al rischio di malignità. Inoltre, EmeritusDX ha aumentato della 35% la propria forza vendita e ha lanciato la piattaforma Syntara™ per strategie di trattamento personalizzate nelle malattie ematologiche.
AccuStem Sciences (OTCQB: ACUT) anunció una expansión de las capacidades de pruebas basadas en la sangre mediante su asociación con EmeritusDX. La colaboración incluye la instalación del sistema Promega Maxwell RSC en EmeritusDX para la extracción de microARN de alto rendimiento a partir de muestras de sangre.
Esta expansión apoyará la prueba MSC de AccuStem, el primer diagnóstico que utiliza microRNA para estratificar nódulos pulmonares según el riesgo de malignidad. Además, EmeritusDX ha aumentado su fuerza de ventas en un 35% y ha lanzado la plataforma Syntara™ para estrategias de tratamiento personalizadas en enfermedades hematológicas.
AccuStem Sciences (OTCQB: ACUT)가 EmeritusDX와의 파트너십을 통해 혈액 기반 검사 능력을 확장했다고 발표했습니다. 이 협력은 혈액 샘플에서 고처리량으로 microRNA를 추출하기 위한 Promega Maxwell RSC 시스템을 EmeritusDX에 설치하는 것을 포함합니다.
이 확장은 마이크로RNA를 이용해 폐 결절의 악성 위험도를 계층화하는 최초의 진단인 AccuStem의 MSC 테스트를 지원합니다. 또한 EmeritusDX는 영업팀을 35% 증가시켰고 혈액질환에 대한 개인 맞춤 치료 전략을 위한 Syntara™ 플랫폼을 출시했습니다.
AccuStem Sciences (OTCQB: ACUT) a annoncé une extension de ses capacités de tests sanguins grâce à son partenariat avec EmeritusDX. La collaboration prévoit l’installation du système Promega Maxwell RSC chez EmeritusDX pour l’extraction à haut débit de microARN à partir d’échantillons de sang.
Cette expansion soutiendra le test MSC d’AccuStem, le premier diagnostic utilisant les microARN pour stratifier les nodules pulmonaires selon le risque de malignité. De plus, EmeritusDX a augmenté ses effectifs commerciaux de 35% et a lancé la plateforme Syntara™ pour des stratégies de traitement personnalisées dans les maladies hématologiques.
AccuStem Sciences (OTCQB: ACUT) kündigte eine Erweiterung der blutbasierten Testmöglichkeiten durch seine Partnerschaft mit EmeritusDX an. Die Zusammenarbeit umfasst die Installation des
Diese Erweiterung wird den MSC-Test von AccuStem unterstützen, den ersten Diagnostik, der MikroRNAs verwendet, um Lungenknötchen in Bezug auf das Malignitätsrisiko zu klassifizieren. Außerdem hat EmeritusDX seine Vertriebsmitarbeiter um 35% erhöht und die Plattform Syntara™ für personalisierte Behandlungsstrategien bei hämatologischen Erkrankungen eingeführt.
AccuStem Sciences (OTCQB: ACUT) أعلنت عن تمديد قدرات الاختبار القائم على الدم من خلال شراكتها مع EmeritusDX. تشمل الشراكة تركيب نظام Promega Maxwell RSC لدى EmeritusDX لاستخراج microRNA عالي الإنتاجية من عينات الدم.
هذا التوسع سيدعم اختبار MSC الخاص بـ AccuStem، أول تشخيص يستخدم microRNA لتصنيف العُقيدات الرئوية وفق مخاطر الأورمة. بالإضافة إلى ذلك، زادت EmeritusDX من قوة مبيعاتها بنسبة 35% وأطلقت منصة Syntara™ لاستراتيجيات العلاج المخصصة في الأمراض الدمويّة.
AccuStem Sciences（OTCQB: ACUT）宣布通过与 EmeritusDX 的伙伴关系扩展血液检测能力。此次合作包括在 EmeritusDX 安装 Promega Maxwell RSC 系统，用于从血样中高通量提取微RNA。
此次扩展将支持 AccuStem 的 MSC 测试，这是第一种使用微RNA来基于恶性风险对肺结节进行分层诊断的测试。此外，EmeritusDX 将销售团队规模扩大了 35%，并推出用于血液疾病个性化治疗策略的 Syntara™ 平台。
- First-to-market diagnostic test (MSC) for lung nodule malignancy risk assessment
- EmeritusDX expanded sales force by 35%
- Launch of innovative Syntara™ platform for personalized treatment strategies
- Implementation of high-throughput Promega Maxwell RSC system enhancing testing capabilities
- None.
PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based testing capabilities in partnership with EmeritusDX, a rapidly growing cancer diagnostics and information company. The two companies are building out their best-in-class product portfolios and respective infrastructures to meet growing clinical demand for non-invasive testing technologies.
A key milestone in this expansion is the installation of the Promega Maxwell RSC system at EmeritusDX, enabling consistent, high-throughput extraction of microRNAs (miRNAs) from blood samples. This capability will power AccuStem’s MSC test, the first diagnostic on the market to use miRNAs to more accurately stratify lung nodules according to their risk of malignancy. By offering this novel test that has a strong foundation of data published in top-tier scientific journals, the companies aim to deliver value to patients and their care teams as well as long-term differentiation in the diagnostics landscape.
“We continue to see significant progress with the MSC technology transfer into EmeritusDX’s laboratories,” added Wendy Blosser, Chief Executive Officer of AccuStem Sciences. “With the right infrastructure and teams in place, we are accelerating the path to market for MSC and laying the groundwork for additional tests in the future. This is about delivering reliable, innovative solutions to patients while also creating value for our stakeholders.”
To further support growth, EmeritusDX has expanded its sales force by
“These initiatives represent both a clinical and commercial inflection point,” said Robert Embree, Chief Executive Officer of EmeritusDX. “By investing in cutting-edge technology and specialized expertise, we are creating a scalable foundation for innovation that strengthens our competitive position, supports physicians, and ultimately improves patient outcomes. Blood-based testing is at the heart of this vision, and we see it as a core driver of our growth.”
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness”, we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.
For more information, please visit www.accustem.com.
About Emeritus
EmeritusDX is a leading cancer diagnostics and information company specializing in the delivery of actionable clinical insights. From our state-of-the-art laboratory, we provide testing that supports the accurate diagnosis and effective treatment of cancer. We proudly partner with hospital and private pathology laboratories, biotechnology firms, academic institutions, contract research organizations, and pharmaceutical development companies. Our partners rely on the precision and timeliness of our results—and we are unwavering in our commitment to excellence.
Forward-Looking Statements
This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. AccuStem Sciences, Inc. assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Investor Contact:
Jeff Fensterer
Email: investors@accustem.com
FAQ
What is AccuStem Sciences' (ACUT) new MSC test used for?
How is EmeritusDX expanding its capabilities with AccuStem Sciences?
What is the Syntara™ platform launched by EmeritusDX?
How will the partnership between AccuStem Sciences and EmeritusDX benefit patients?
What technology is being used for AccuStem's blood-based testing capabilities?
